• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Meta-Analysis: Idiopathic Polyhydramnios and Adverse Pregnancy Outcomes

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Pagan et al. (Ultrasound in Obstetrics & Gynecology, 2022) analyzed pregnancy outcomes in singleton pregnancies with idiopathic polyhydramnios

METHODS:

  • Systematic review and meta-analysis
  • Study Inclusion criteria
    • Prospective and retrospective studies
    • Presence of a control group (normal amniotic fluid volume)
    • Singleton pregnancies
    • Idiopathic polyhydramnios: Identified using sonographic amniotic fluid volume assessment
  • Study design
    • Polyhydramnios definition: Four-quadrant AFI with polyhydramnios ≥24 cm or single deepest pocket (SDP) ≥8 cm | AFI >25 cm also included (commonly used definition)
    • Idiopathic polyhydramnios: No etiology identified on ultrasound
    • Effect estimates expressed as odds ratio (OR) and its corresponding 95% CI
    • Data pooled using random effects model
  • Primary outcome
    • Intrauterine fetal demise
  • Secondary outcomes
    • NICU admission
    • Macrosomia: ≥4000 g birthweight
    • 5 minute APGAR score <7
    • Neonatal death
    • Low birthweight
    • Malpresentation
    • Cesarean delivery

RESULTS:

  • 12 studies
    • Idiopathic polyhydramnios patients: 2392 | Controls: 160,135
  • Pregnancies complicated by idiopathic polyhydramnios had higher odds of
    • Neonatal death: OR 8.68 (95% CI, 2.91 to 25.87)
    • Intrauterine fetal demise: OR 7.64 (95% CI, 2.50 to 23.38)
    • NICU admission: OR 1.94 (95% CI, 1.45 to 2.59)
    • 5-minute APGAR score <7: OR 2.21 (95% CI, 1.34 to 3.62)
    • Macrosomia: OR 2.93 (95% CI, 2.39 to 3.59)
    • Malpresentation: OR 2.73 (95% CI, 2.06 to 3.61)
    • Cesarean delivery: OR 2.31 (95% CI, 1.79 to 2.99)

CONCLUSION:

  • Pregnancies with idiopathic polyhydramnios are associated with increased odds of adverse pregnancy outcomes, particularly neonatal death and intrauterine fetal demise
  • Antenatal fetal surveillance may be a consideration for pregnancies with idiopathic polyhydramnios
  • The authors state

Currently, there is insufficient data on the threshold of the AFV (mild, moderate or severe) at which antenatal testing should be initiated

Future investigations are needed to determine an AFV threshold above which antenatal testing would be helpful

Learn More – Primary Sources:

Idiopathic polyhydramnios and pregnancy outcomes: systematic review and meta-analysis

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Practical obstetrics info for your women's healthcare practice
Polyhydramnios – Possible Causes and Next Steps
Deepest Pocket or AFI When Performing Prenatal Ultrasound?  
Can Sildenafil Citrate Help in the Management of Oligohydramnios?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site